Drug Combination Details

General Information of the Combination (ID: C99457)
Name Epigallocatechin gallate   NP Info  + Tamoxifen   Drug Info 
Structure +
Disease
Breast cancer [ICD-11: 2C60]
Investigative [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [1]
                    Molecule(s)
                    Regulation		 Down-regulation Expression CYP1B1  Molecule Info 
Pathway MAP
Down-regulation Expression EGFR  Molecule Info 
Pathway MAP
Down-regulation Expression mTOR  Molecule Info 
Pathway MAP
                    In-vitro Model MDA-MB-231 CVCL_0062 Breast adenocarcinoma Homo sapiens
MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
                    In-vivo Model Female CD1 athymic nude mice were inoculated into the right flank with MDA-MB-231 cells (2*106/50L matrigel), which were left to form palpable tumours.
                    Experimental
                    Result(s)		 Tamoxifen at realistic doses (75 mug kg(-1)) can suppress the growth of ER-negative breast cancer when combined with EGCG. The dominant mechanism for tumour suppression is the concomitant decrease in tumour protein expressions of mTOR and the EGFR.
                    Experiment 2 Reporting the Effect of This Combination [2]
                    Biological
                    Regulation		 Up-regulation Apoptosis
                    In-vitro Model MCF-7 CVCL_0031 Invasive breast carcinoma Homo sapiens
T-47D CVCL_0553 Invasive breast carcinoma Homo sapiens
MDA-MB-231 CVCL_0062 Breast adenocarcinoma Homo sapiens
Hs 578T CVCL_0332 Invasive breast carcinoma Homo sapiens
MCF-12A CVCL_3744 Healthy Homo sapiens
                    Experimental
                    Result(s)		 Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells.
References
Reference 1 A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer. 2008 Oct 7;99(7):1056-63.
Reference 2 Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs. 2004 Oct;15(9):889-97.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link